These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 27250643)

  • 1. Enhancement of anti-STLV-1/HTLV-1 immune responses through multimodal effects of anti-CCR4 antibody.
    Sugata K; Yasunaga J; Miura M; Akari H; Utsunomiya A; Nosaka K; Watanabe Y; Suzushima H; Koh KR; Nakagawa M; Kohara M; Matsuoka M
    Sci Rep; 2016 Jun; 6():27150. PubMed ID: 27250643
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of simian T-cell leukemia virus type 1 in naturally infected Japanese macaques as a model of HTLV-1 infection.
    Miura M; Yasunaga J; Tanabe J; Sugata K; Zhao T; Ma G; Miyazato P; Ohshima K; Kaneko A; Watanabe A; Saito A; Akari H; Matsuoka M
    Retrovirology; 2013 Oct; 10():118. PubMed ID: 24156738
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mogamulizumab, an anti-CCR4 antibody, targets human T-lymphotropic virus type 1-infected CD8+ and CD4+ T cells to treat associated myelopathy.
    Yamauchi J; Coler-Reilly A; Sato T; Araya N; Yagishita N; Ando H; Kunitomo Y; Takahashi K; Tanaka Y; Shibagaki Y; Nishioka K; Nakajima T; Hasegawa Y; Utsunomiya A; Kimura K; Yamano Y
    J Infect Dis; 2015 Jan; 211(2):238-48. PubMed ID: 25104771
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cellular Immune Responses against Simian T-Lymphotropic Virus Type 1 Target Tax in Infected Baboons.
    Castro I; Giret TM; Magnani DM; Maxwell HS; Umland O; Perry JK; Pecotte JK; Brasky KM; Barber GN; Desrosiers RC; Watkins DI
    J Virol; 2016 Jun; 90(11):5280-5291. PubMed ID: 26984729
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Isolation and characterization of a new simian T-cell leukemia virus type 1 from naturally infected celebes macaques (Macaca tonkeana): complete nucleotide sequence and phylogenetic relationship with the Australo-Melanesian human T-cell leukemia virus type 1.
    Ibrahim F; de Thé G; Gessain A
    J Virol; 1995 Nov; 69(11):6980-93. PubMed ID: 7474117
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mogamulizumab (Anti-CCR4) in HTLV-1-Associated Myelopathy.
    Sato T; Coler-Reilly ALG; Yagishita N; Araya N; Inoue E; Furuta R; Watanabe T; Uchimaru K; Matsuoka M; Matsumoto N; Hasegawa Y; Yamano Y
    N Engl J Med; 2018 Feb; 378(6):529-538. PubMed ID: 29414279
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High simian T-cell leukemia virus type 1 proviral loads combined with genetic stability as a result of cell-associated provirus replication in naturally infected, asymptomatic monkeys.
    Gabet AS; Gessain A; Wattel E
    Int J Cancer; 2003 Oct; 107(1):74-83. PubMed ID: 12925959
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of a HTLV-1 subunit vaccine in prevention of experimental STLV-I infection in Macaca nemestrina.
    Dezzutti CS; Frazier DE; Lafrado LJ; Olsen RG
    J Med Primatol; 1990; 19(3-4):305-16. PubMed ID: 2172541
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HTLV-1 Viral Factor HBZ Induces CCR4 to Promote T-cell Migration and Proliferation.
    Sugata K; Yasunaga J; Kinosada H; Mitobe Y; Furuta R; Mahgoub M; Onishi C; Nakashima K; Ohshima K; Matsuoka M
    Cancer Res; 2016 Sep; 76(17):5068-79. PubMed ID: 27402079
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune recognition of genetically diverse simian T-cell lymphotropic virus type I isolates.
    Lazo A; Bailer RT; Blakeslee JR; Yanagihara R; Stevens VC; Kramer L; Lairmore MD
    Arch Virol; 1995; 140(2):307-23. PubMed ID: 7535998
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Simian T Lymphotropic Virus 1 Infection of Papio anubis:
    Termini JM; Magnani DM; Maxwell HS; Lauer W; Castro I; Pecotte J; Barber GN; Watkins DI; Desrosiers RC
    J Virol; 2017 Oct; 91(20):. PubMed ID: 28724769
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-CCR4 monoclonal antibody mogamulizumab for the treatment of EBV-associated T- and NK-cell lymphoproliferative diseases.
    Kanazawa T; Hiramatsu Y; Iwata S; Siddiquey M; Sato Y; Suzuki M; Ito Y; Goshima F; Murata T; Kimura H
    Clin Cancer Res; 2014 Oct; 20(19):5075-84. PubMed ID: 25117294
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tax-inducible production of CC chemokine ligand 22 by human T cell leukemia virus type 1 (HTLV-1)-infected T cells promotes preferential transmission of HTLV-1 to CCR4-expressing CD4+ T cells.
    Hieshima K; Nagakubo D; Nakayama T; Shirakawa AK; Jin Z; Yoshie O
    J Immunol; 2008 Jan; 180(2):931-9. PubMed ID: 18178833
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Furin-dependent CCL17-fused recombinant toxin controls HTLV-1 infection by targeting and eliminating infected CCR4-expressing cells in vitro and in vivo.
    Hiyoshi M; Okuma K; Tateyama S; Takizawa K; Saito M; Kuramitsu M; Araki K; Morishita K; Okada S; Yamamoto N; Biragyn A; Yamaguchi K; Hamaguchi I
    Retrovirology; 2015 Aug; 12():73. PubMed ID: 26289727
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of an HTLV-1 subunit vaccine in prevention of a STLV-1 infection in pig-tailed macaques.
    Dezzutti CS; Frazier DE; Olsen RG
    Dev Biol Stand; 1990; 72():287-96. PubMed ID: 2178125
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dynamic interaction between STLV-1 proviral load and T-cell response during chronic infection and after immunosuppression in non-human primates.
    Souquière S; Mouinga-Ondemé A; Makuwa M; Hermine O; Kazanji M
    PLoS One; 2009 Jun; 4(6):e6050. PubMed ID: 19557183
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mogamulizumab and the treatment of CCR4-positive T-cell lymphomas.
    Remer M; Al-Shamkhani A; Glennie M; Johnson P
    Immunotherapy; 2014; 6(11):1187-206. PubMed ID: 25496334
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vaccination with short-term-cultured autologous PBMCs efficiently activated STLV-1-specific CTLs in naturally STLV-1-infected Japanese monkeys with impaired CTL responses.
    Hasegawa A; Murata M; Fujikawa T; Katagiri K; Nagano Y; Masuda T; Kuramitsu M; Nakajima S; Fujisawa JI; Okuma K; Grover P; Kidiga M; Akari H; Kannagi M
    PLoS Pathog; 2023 Feb; 19(2):e1011104. PubMed ID: 36730466
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduction of regulatory T cells by Mogamulizumab, a defucosylated anti-CC chemokine receptor 4 antibody, in patients with aggressive/refractory mycosis fungoides and Sézary syndrome.
    Ni X; Jorgensen JL; Goswami M; Challagundla P; Decker WK; Kim YH; Duvic MA
    Clin Cancer Res; 2015 Jan; 21(2):274-85. PubMed ID: 25376389
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Application of Anti-CCR4 Monoclonal Antibody.
    Ueda R
    Oncology; 2015; 89 Suppl 1():16-21. PubMed ID: 26550987
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.